Abstract | BACKGROUND: METHODS: This is a retrospective cohort study of 54 eyes from 54 subfoveal exudative AMD patients (tAMD 24, PCV 30 eyes). Three consecutive IVR treatments (0.5 mg) were performed every month, followed by re- injections as needed. Change in the best-corrected visual acuity (BCVA) and central retinal thickness (CRT) were then compared between the tAMD and PCV groups over 12 months of follow-up. RESULTS: The mean BCVA was significantly improved (-0.11 logMAR units) at month 3 after the initial IVR (p <0 .001, Wilcoxon signed-rank test), and was sustained up to 12 months in all AMD patients (p =0.02). In the subgroup analysis, the tAMD group showed a significant improvement in their mean BCVA (-0.06, -0.17, -0.15 and -0.16 logMAR units at 1, 3, 6 and 12 months, respectively), but there was only a slight but non-significant improvement in the PCV group. The improvement in the BCVA was significantly greater in the tAMD group than in the PCV group (p = 0.043, repeated measures ANOVA) over 12 months. Both phenotypes showed significant improvements in the CRT during 12 months after the initial IVR. CONCLUSIONS: IVR is an effective therapy for tAMD and PCV in the BCVA improvement in Japanese patients over 12 months of follow-up. The phenotype of tAMD showed a significantly better outcome with IVR than PCV in terms of BCVA improvement.
|
Authors | Wataru Matsumiya, Shigeru Honda, Sentaro Kusuhara, Yasutomo Tsukahara, Akira Negi |
Journal | BMC ophthalmology
(BMC Ophthalmol)
Vol. 13
Pg. 10
(Apr 04 2013)
ISSN: 1471-2415 [Electronic] England |
PMID | 23557322
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Angiogenesis Inhibitors
- Antibodies, Monoclonal, Humanized
- Ranibizumab
|
Topics |
- Aged
- Angiogenesis Inhibitors
(administration & dosage)
- Antibodies, Monoclonal, Humanized
(administration & dosage)
- Choroid Diseases
(drug therapy, pathology, physiopathology)
- Female
- Follow-Up Studies
- Humans
- Intravitreal Injections
- Logistic Models
- Macular Degeneration
(drug therapy, pathology, physiopathology)
- Male
- Middle Aged
- Polyps
(drug therapy)
- Ranibizumab
- Retrospective Studies
- Visual Acuity
|